{"id":"20b7e02d-0f91-4b57-9ae7-fa20a52933ef","arxiv_id":"2501.07789","paper_version":1,"verdict":"CONDITIONAL","confidence":"MODERATE","novelty_score":4.0,"correctness_risk":"medium","formal_verification":"none","parameter_count":3,"one_line_summary":"In Medicare heart failure patients, tailored machine learning rules choosing furosemide or torsemide at discharge were estimated to add about 9 to 11 days of survival within one year compared with prescribing torsemide to everyone.","lead":"This paper applies three machine learning methods to Medicare claims data to find whether heart failure patients should be prescribed furosemide or torsemide at discharge. It reports that a patient-specific rule adds roughly 9 to 11 days alive or free of heart failure readmission over a one-size-fits-all torsemide rule within one year.","discovery_kind":"new_application","skeptic_critique":{"model":"deepseek-v4-flash","headline":"The IPW value-function estimate assumes no unmeasured confounding of loop diuretic choice; Medicare claims may miss frailty and renal severity, so Table 5's 5–11 day gains may be biased; a negative-control outcome test would adjudicate.","rationale":"The reader's CONDITIONAL verdict already rests on the unmeasured-confounding assumption, and my stress test confirms this is the most load-bearing threat. The central benefit estimate is an inverse-probability-weighted value-function contrast; its consistency requires correct propensity scores. The paper's own limitations section discusses inferential challenges but does not quantify bias under unmeasured confounding. A negative-control outcome is a concrete way to test this: if a null-effect outcome yields similar gains, the real-world result is likely artifact. I do not upgrade the verdict to REJECT because the methods are established and the causal assumption is a standard, testable condition; conditional acceptance with a demand for falsification analysis is appropriate. I also note the abstract/Table 5 mismatch (composite vs. days alive) as a secondary reporting issue, not the primary threat to the causal claim.","tokens_in":8139,"tokens_out":6090,"duration_ms":68378,"concrete_test":"Run a negative-control falsification: apply the identical three-learner, IPW-based value-function pipeline to a one-year outcome that loop diuretic choice cannot plausibly affect but that shares the same confounding structure, for example time to first non-heart-failure, non-cardiovascular elective hospital admission or death from external causes. Under the causal null the estimated value-function differences should be centered at zero. If the tailored rule again shows a 5–10 day 'benefit' on the negative control, that is direct evidence that residual confounding, not treatment efficacy, drives the Table 5 result. Reporting standardized covariate balance after inverse probability weighting for the ten importance-selected covariates would further corroborate whether the propensity model is adequately specified.","verdict_should_be":"UNCHANGED","load_bearing_attack":"To establish that the tailored rule genuinely adds roughly a week or more of survival (Table 5), the value function V(d) must identify potential-outcome means. The IPW estimator in the 'Treatment Rule Estimation' section is only consistent if the propensity score π(A|X) includes all common causes of loop diuretic choice and the survival/composite reward. The 'Covariates' section lists variables derived from six months of Medicare claims: demographics, some comorbidities, drug claims, and a claims-based ejection fraction algorithm. It does not include measured ejection fraction, renal function labs (creatinine/eGFR), electrolytes, BNP, functional status, or clinician's prognostic judgment. These are precisely the factors that drive choice between furosemide and torsemide: torsemide is often used in patients with diuretic resistance or worse congestion. Random forest estimation of π reduces functional-form assumptions but cannot remove confounding by unmeasured U. Under residual confounding, the estimated value-function contrast V(d*) − V(universal torsemide) is biased, so the reported 4.7 to 10.7 additional days need not equal the causal effect of adopting the rule. This is the load-bearing assumption: if it fails, the central claim of improved survival under an optimal rule is unsupported, regardless of learner performance or internal reporting consistency.","agreement_with_reader":"agree"},"referee_report":{"model":"deepseek-v4-flash","summary":"The paper proposes to identify optimal individualized loop diuretic (furosemide vs. torsemide) prescribing rules for heart failure patients using three precision medicine learners: random forests, residual weighted learning, and efficient augmentation relaxed learning. After two hypothetical examples illustrating effect heterogeneity, it applies the learners to 66,741 Medicare fee-for-service beneficiaries with a recent heart failure hospitalization and a new loop diuretic prescription. The value of a treatment rule is estimated through inverse probability weighting with a propensity score estimated by random forests, and rules are evaluated with 10-fold cross-validation against a universal torsemide rule. The real-world results (Table 5) report gains of 7.8-10.7 additional days alive and 4.7-7.6 additional days alive free of heart failure readmission, with confidence intervals for the composite outcome including zero for two of the three learners. The abstract, however, states that the largest gain is approximately 9 days for survival time free of heart failure readmission, which is inconsistent with Table 5.","tokens_in":8400,"tokens_out":4973,"duration_ms":49379,"significance":"If the central claims were fully supported, this would be a useful demonstration of how modern individualized treatment rule methods can be applied to claims-based pharmacoepidemiology, potentially informing future decision support tools. The use of three distinct learners, real Medicare data, and a clinically meaningful outcome is a strength. However, the paper's current form contains a direct internal inconsistency between the abstract and the principal results table, an apparently erroneous duplication in the toy-example table, and no quantitative treatment of unmeasured confounding—the last being essential for any causal interpretation of the estimated value-function contrasts. These issues currently prevent the paper from supporting its headline conclusions.","major_comments":[{"comment":"The abstract claims that \"the improvement under the optimal treatment rule in the real-world setting is greatest (additional ~9 days under the tailored rule) for survival time free of heart failure readmission.\" This is contradicted by Table 5, where the largest composite-outcome gain is 7.6 days (Residual Weighted Learner, 95% CI 2.2-13.0), and the largest overall gain is 10.7 days for days alive (Efficient Augmentation Relaxed Learner). Please correct the abstract so that it accurately represents the reported results, and ensure that all text descriptions of the main findings match Table 5.","section":"Abstract and Table 5"},{"comment":"The two panels of Table 3, labeled \"Has T2DM\" and \"Does not have T2DM,\" contain identical numbers. As a result, the three-modifier toy example does not actually demonstrate any additional effect modification by T2DM, and the claimed reduction in absolute risk from 0.17 (Table 2) to 0.15 (Table 4) is not supported by the displayed data. A direct recomputation from Table 3 (treating the two panels as distinct only in name) yields a tailored-rule risk different from 0.15. Please correct the table or the associated text and recompute the corresponding risks.","section":"Table 3 (toy example)"},{"comment":"The causal interpretation of the value-function contrast V(d*) - V(universal torsemide) relies on the assumption that the propensity score π(A|X) includes all common causes of loop diuretic choice and the survival/composite reward. The covariates listed in the Covariates section are derived from six months of Medicare claims and do not include measured ejection fraction, renal function laboratories (creatinine/eGFR), electrolytes, BNP, functional status, or clinician's prognostic judgment. These are plausibly related to both diuretic selection and the outcome. Without a negative-control outcome, a quantitative sensitivity analysis, or at minimum a prominent and detailed discussion of this limitation, the estimated 5-11 day gains may reflect residual confounding rather than a causal effect of adopting the tailored rule. Please add such an analysis or substantially soften the causal language throughout.","section":"Treatment Rule Estimation and Covariates"}],"minor_comments":[{"comment":"In the 'Methods' paragraph, the text says 'We evaluated the expected value function (time to each outcome) for each precision medicine method (Table 3).' This should refer to Table 5, which contains the real-world results.","section":"Methods"},{"comment":"The displayed value function V(d) = E[Y * I{A=d(X)} / π(A;X)] contains a trailing '2' that appears to be a typographical artifact. If the intent is to use the inverse probability weighted estimator adjusted for estimated propensity scores, please write the formula without the extraneous character.","section":"Treatment Rule Estimation"},{"comment":"The description of the RIST imputation states that the imputation was repeated 2 times; it would be helpful to briefly justify this choice, since multiple imputation typically requires more repetitions to reflect between-imputation variability.","section":"Censoring"},{"comment":"The table would be easier to interpret if it also reported the proportion of patients for whom each learner recommended torsemide rather than furosemide, as the clinical meaning of a tailored rule depends on which patients would be switched.","section":"Table 5"}],"recommendation":"major_revision","confidential_remarks":"The abstract misstates the paper's own headline result, and the toy-example table contains duplicated rows; these are fixable but must be addressed. The unmeasured confounding issue is substantive: given that the data are observational claims, the causal claim is only as strong as the no-unmeasured-confounding assumption. A negative-control outcome or E-value style sensitivity analysis would considerably strengthen the manuscript. The manuscript would also benefit from a clearer statement of what is new methodologically, since several of the learners are authored by the senior author and the application itself is the primary contribution."},"author_rebuttal":null,"desk_editor":{"model":"deepseek-v4-flash","letter":"First, the useful thing to know: this paper is a serious, readable demonstration of three precision medicine learners on a real pharmacoepidemiology question—choosing between furosemide and torsemide at discharge for Medicare heart failure patients. It does several things well. It walks through a toy example that clearly shows why a tailored rule can beat a universal rule, and it applies the learners carefully with 10-fold cross-validation, variable importance, and RIST imputation for censoring. The primary result for days alive is consistent: all three learners show positive gains (7.8 to 10.7 days) with confidence intervals excluding zero. That is the paper's real contribution, and it is plausible.\n\nThe soft spots are real but not fatal. The abstract says the improvement is greatest—roughly 9 days—for survival free of heart failure readmission. Table 5 shows the opposite: the composite outcome gains are smaller (4.7 to 7.6 days) and only one of three confidence intervals excludes zero. The abstract is simply wrong about which outcome is strongest. That needs fixing before publication.\n\nMore substantively, the causal claim assumes no unmeasured confounding. The covariates come from six months of Medicare claims; there is no measured ejection fraction, no creatinine/eGFR, no BNP, no functional status, no clinician's prognostic judgment. Those are exactly the variables that drive diuretic choice, because torsemide is often prescribed for patients with worse congestion or diuretic resistance. If unmeasured factors push both toward torsemide and toward worse outcomes, the estimated value-function differences are biased. The authors do not test this. A negative-control outcome or an E-value analysis would help. This is a standard limitation of observational claims-based precision medicine, but the paper should own it more prominently.\n\nAlso, no code or data are provided. That makes the analysis impossible to reproduce, and for a methods application paper, that is a minor but unnecessary barrier.\n\nWho is this for? Epidemiologists and biostatisticians who want a clear worked example of how to implement residual weighted learning and efficient augmentation relaxed learning in a real claims dataset. Clinicians in heart failure who want to know whether a tailored loop diuretic rule is worth pursuing will find the effect sizes modest and the causal caveats important.\n\nMy recommendation: send it to peer review. The primary result holds up internally, the methods are used correctly, and the topic matters. A good referee will ask for the abstract to be corrected, a sensitivity analysis for unmeasured confounding, and ideally the analysis scripts.","headline":"Solid, honest application of established precision medicine methods to furosemide vs torsemide in Medicare; the days-alive result is consistently positive, but the abstract's 9-day claim is for the wrong outcome and unmeasured confounding remains the key threat.","tokens_in":8941,"tokens_out":2733,"would_cite":true,"duration_ms":26382,"reading_group":"yes","serious_thinker":"yes","would_accept_peer_review":true},"rs_alignment":null,"lean_confirmation":null,"pith_extraction":{"msc":["62P10"],"pacs":[],"model":"deepseek-v4-flash","headline":"This paper claims that data-driven individualized treatment rules for choosing between furosemide and torsemide can give heart failure patients roughly 8 to 11 more days alive within a year than a one-drug-fits-all rule.","keywords":["precision medicine","optimal treatment rule","heart failure","loop diuretics","value function","residual weighted learning","random forests","Medicare claims"],"falsifier":"Measure an unmeasured confounder—say, a validated frailty index or physician-documented prognosis—in a validation cohort with the same inclusion criteria, re-estimate the propensity score with it included, and recompute the value-function differences. If the added days shrink toward zero or the optimal rule changes materially, the central claim is falsified as stated; alternatively, a randomized SMART trial assigning patients by the learned rule could settle the causal question directly.","tokens_in":7962,"feed_emoji":"🫀","tokens_out":10464,"duration_ms":91109,"temperature":0.7,"pith_summary":"This paper argues that comparing a single average treatment effect can mask meaningful differences in how patients respond, and that tailored treatment rules can do better. Using Medicare claims from heart failure patients discharged on a loop diuretic, it applies three machine-learning methods to choose between furosemide and torsemide for each individual. The paper reports that the tailored rules add roughly 8 to 11 days alive within one year compared with prescribing torsemide to everyone, and its hypothetical examples show tailoring can cut absolute mortality risk substantially. A careful reader would care because it offers a template for turning administrative health data into individualized prescribing recommendations.","feed_headline":"Choosing diuretics by algorithm adds 8-11 days alive","feed_subtitle":"Precision rules beat a one-drug-fits-all loop diuretic strategy in Medicare heart failure patients.","key_machinery":"The central object is the treatment rule $d(x)$, a map from baseline covariates $X$ to a treatment $A \\in \\{-1,1\\}$ (torsemide vs. furosemide). Each learner optimizes a value function $V(d) = E[\\,Y\\, I\\{A=d(X)\\}/\\pi(A;X)\\,]$, the inverse-probability-weighted expected reward (here, days to death or to the composite of death and heart failure readmission), with $\\pi(A;X)$ the propensity score estimated by random forests. The three learners are random forests, residual weighted learning (which weights outcomes by residuals from a fitted outcome model), and efficient augmentation and relaxation learning (which adds a doubly robust correction). Censoring is handled by recursively imputed survival trees, and dimensionality is reduced by a variable-importance step using out-of-bag Gini impurity.","core_discovery":"On the paper's own terms, the central discovery is that an optimal treatment rule—a map from each patient's clinical history to a choice of furosemide or torsemide—can be learned from observational claims data and outperforms a universal rule. In the real-world Medicare cohort, all three learners found positive gains in days alive within one year (7.8 to 10.7 days, with confidence intervals excluding zero), and the abstract highlights roughly 9 additional days as the headline improvement. The toy examples show that, when effect heterogeneity is present, a tailored rule can lower absolute mortality risk far below either one-treatment-fits-all option. The paper frames this as evidence that precision medicine methods built on causal inference can identify useful individualized treatment decisions in pharmacoepidemiology.","pith_inferences":["The paper's abstract emphasizes a roughly 9-day gain for 'survival time free of heart failure readmission,' but Table 5 shows the larger and more statistically reliable gains are in days alive; readers should treat the composite-readmission result as less settled than the mortality result.","A 7-to-11-day gain in a 365-day horizon is modest, and whether it is worth acting on depends on the cost, side effects, and patient preferences around switching diuretics, which the paper does not quantify.","Because only furosemide and torsemide were compared and the inclusion criteria required no prior loop diuretic use in six months, the rule may not generalize to patients already on a diuretic or to those for whom bumetanide is appropriate; extending to three treatments would require multi-arm optimal-rule methods.","The toy examples show tailoring helps most when interactions are unknown; in the real data, the ten covariates with the highest variable-importance scores (with age the most important) form a candidate list of effect modifiers that future studies could measure prospectively."],"forward_implications":["If the estimated rules were implemented at discharge, clinicians would switch some patients from furosemide to torsemide (or vice versa) according to claims-based variables such as age, COPD, atrial fibrillation, and prior medications, with an expected gain of about a week of life in the following year.","The similarity of results across three different learners suggests the tailoring signal is not an artifact of one algorithm, strengthening the case that the benefit is real.","For the composite outcome of readmission or death, gains were smaller (up to 7.6 days) and two of the three confidence intervals included zero, so the strongest evidence is for marginal survival rather than readmission avoidance.","A prospective SMART randomized trial that assigns patients using the learned rule would be the natural next test of whether these observational gains are causally reproducible.","Because the value function requires estimating the propensity score, the rule is only as credible as the covariates used; adding richer clinical data such as measured ejection fraction or laboratory values may change the rule."],"supporting_citations":[{"why":"Defines residual weighted learning, one of the three learners used to estimate the optimal treatment rule.","marker":"[6]"},{"why":"Defines efficient augmentation and relaxation learning, the doubly robust learner with relaxed model specification assumptions.","marker":"[18]"},{"why":"Defines random forests, used both as a learner and for estimating the propensity score.","marker":"[19]"},{"why":"Introduces outcome weighted learning, the conceptual basis for the value function weighting with inverse probability weights.","marker":"[20]"},{"why":"Supplies the 20% Medicare sample used for the real-world cohort.","marker":"[21]"},{"why":"Provides the claims-based ejection fraction prediction used as a clinical covariate.","marker":"[24]"},{"why":"Gives the loop diuretic dose equivalency used to adjust for dose differences between furosemide and torsemide.","marker":"[25]"},{"why":"Introduces recursively imputed survival trees for handling censoring in the event-time outcomes.","marker":"[28]"}],"fun_headline_variants":["Algorithm picks diuretic, adds ~9 days alive","Precision diuretic rule gains 8-11 days in heart failure","Tailored drug choice extends survival by weeks? No, days","Machine learning beats one-size-fits-all diuretic strategy"],"cache_read_input_tokens":3200,"weakest_assumption_plain":"The load-bearing premise is that the Medicare claims covariates capture all factors that affect both which loop diuretic a patient receives and how long they survive, so the inverse-probability-weighted value function identifies a true causal effect of treatment choice rather than a reflection of unmeasured differences such as frailty or physician prognosis.","fun_headline_variants_meta":{"raw":{"variants":["Algorithm picks diuretic, adds ~9 days alive","Precision diuretic rule gains 8-11 days in heart failure","Tailored drug choice extends survival by weeks? No, days","Machine learning beats one-size-fits-all diuretic strategy"]},"model":"deepseek-v4-flash","effort":"low","cost_usd":0.00019,"raw_usage":{"total_tokens":1323,"prompt_tokens":911,"completion_tokens":412,"prompt_tokens_details":{"cached_tokens":384},"prompt_cache_hit_tokens":384,"prompt_cache_miss_tokens":527,"completion_tokens_details":{"reasoning_tokens":342}},"tokens_in":527,"tokens_out":412,"duration_ms":4950,"temperature":1.0,"reasoning_tokens":342,"cache_read_input_tokens":384,"cache_creation_input_tokens":0},"cache_creation_input_tokens":0},"created_at":"2026-08-10T20:35:22.798138+00:00","model_set":{"reader":"deepseek-v4-flash"},"falsifier":"Measure an unmeasured confounder—say, a validated frailty index or physician-documented prognosis—in a validation cohort with the same inclusion criteria, re-estimate the propensity score with it included, and recompute the value-function differences. If the added days shrink toward zero or the optimal rule changes materially, the central claim is falsified as stated; alternatively, a randomized SMART trial assigning patients by the learned rule could settle the causal question directly.","supporting_citations":[],"review_version":1}